GFM
OCUL icon

GF Fund Management’s Ocular Therapeutix OCUL Stock Holding History

GF Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.2K Sell
4,607
-177
-4% -$1.6K ﹤0.01% 397
2026
Q1 		$40.5K Buy
4,784
+599
+14% +$5.71K ﹤0.01% 423
2025
Q4 		$50.8K Buy
4,185
+442
+12% +$5.37K ﹤0.01% 405
2025
Q3 		$43.8K Sell
3,743
-283
-7% -$3.38K ﹤0.01% 409
2025
Q2 		$37.4K Hold
4,026
– – ﹤0.01% 445
2025
Q1 		$29.5K Buy
4,026
+725
+22% +$5.57K ﹤0.01% 461
2024
Q4 		$28.2K Buy
+3,301
New +$32.2K ﹤0.01% 438

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GF Fund Management's OCUL Position: Q2 2026 in Review

GF Fund Management reduced its Ocular Therapeutix (OCUL) stake by 3.7% in Q2 2026, selling an estimated $1.6K and leaving 4,607 shares worth $45.2K. The position accounts for ﹤0.01% of the portfolio, ranked #397.

GF Fund Management first reported a position in OCUL in Q4 2024 and has held it in 7 quarters since. The position peaked at $50.8K in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • GF Fund Management held 4,607 shares of Ocular Therapeutix worth $45.2K as of Q2 2026.
  • GF Fund Management sold 177 Ocular Therapeutix shares in Q2 2026, an estimated $1.6K.
  • Ocular Therapeutix made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #397 holding.
  • GF Fund Management first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Ocular Therapeutix position peaked at $50.8K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.